Eton Pharmaceuticals to Report Fourth Quarter 2022 Financial Results on Thursday, March 16, 2023

Rhea-AI Summary

Eton Pharmaceuticals, Inc. (Nasdaq: ETON) is set to report its fourth quarter 2022 financial results on March 16, 2023, during a conference call at 4:30 p.m. ET. The call will be accessible via a live audio webcast for investors and includes a segment for emailed questions.

Eton is focused on treatments for rare diseases and currently has three FDA-approved products: ALKINDI SPRINKLE®, Carglumic Acid tablets, and Betaine Anhydrous for Oral Solution. The company is also developing three late-stage pipeline candidates and receives royalties from other FDA-approved products.

Positive

• Company has three FDA-approved products: ALKINDI SPRINKLE®, Carglumic Acid tablets, and Betaine Anhydrous for Oral Solution.
• Developing three late-stage pipeline candidates.
• Receiving royalties on three FDA-approved products.

Negative

• None.

DEER PARK, Ill., March 07, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report fourth quarter 2022 financial results on Thursday, March 16, 2023. Management will host a conference call and live audio webcast to discuss these results at 4:30 p.m. ET (3:30 p.m. CT).

Register* (Audio Only)  Click Here

In addition to taking live questions from participants on the conference call, management will be answering emailed questions from investors. Investors can email questions to: investorrelations@etonpharma.com.

The live webcast can be accessed on the Investors section of Eton’s website at https://ir.etonpharma.com/. An archived webcast will be available on Eton’s website approximately two hours after the completion of the event and for 30 days thereafter.

* Conference call participants should register to obtain their dial-in and passcode details. Please be sure to register using a valid email address.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc. is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company currently has three FDA approved products in ALKINDI SPRINKLE®, Carglumic Acid tablets, and Betaine Anhydrous for Oral Solution, and three late-stage pipeline candidates under development with dehydrated alcohol injection, ZENEO® hydrocortisone autoinjector, and ET-400. In addition, the Company receives royalties on three FDA-approved products and is entitled to receive milestone payments on other products. For more information, please visit our website at www.etonpharma.com.

Investor Relations:
Lisa M. Wilson, In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com

Source: Eton Pharmaceuticals

FAQ

When will Eton Pharmaceuticals report its fourth quarter 2022 earnings?

Eton Pharmaceuticals will report its fourth quarter 2022 earnings on March 16, 2023.

What is the time of Eton Pharmaceuticals' earnings call?

The earnings call for Eton Pharmaceuticals is scheduled for 4:30 p.m. ET on March 16, 2023.

How can investors participate in Eton Pharmaceuticals' earnings call?

Investors can participate in Eton Pharmaceuticals' earnings call by registering for the live audio webcast available on their website.

What products does Eton Pharmaceuticals currently have FDA approval for?

Eton Pharmaceuticals currently has FDA approval for ALKINDI SPRINKLE®, Carglumic Acid tablets, and Betaine Anhydrous for Oral Solution.

What is the focus of Eton Pharmaceuticals?

Eton Pharmaceuticals is focused on developing and commercializing treatments for rare diseases.